Aligos Therapeutics to Present at Investor Conferences in October

Group 1 - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases, aiming to improve patient outcomes [2] - The company will participate in two upcoming investor conferences in October 2024, including the H.C. Wainwright 8th Annual MASH Virtual Conference and the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference [1] - A live webcast of the events will be available on Aligos' website, with replays accessible for at least 30 days after the presentations [1] Group 2 - Aligos Therapeutics is dedicated to addressing high unmet medical needs in conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and hepatitis B [2] - The company utilizes a science-driven approach and extensive R&D expertise to advance its pipeline of therapeutics [2]